Trial Search Results
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.
Stanford is currently not accepting patients for this trial.
Collaborator: Merck Sharp & Dohme Corp.
- Drug: Ertugliflozin
- Drug: Glipizide
- patient at Stanford Cardiovascular Surgery clinic who is scheduled for cardiac bypass
- history of Diabetes Mellitus Type 2 currently taking metformin or diet-controlled
- allergy or intolerance to interventional medication
- currently taking any anti-diabetic medication other than metformin
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study